Citadel Advisors
SXTP icon

Citadel Advisors’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Citadel Advisors’s Portfolio SXTP Stock Details SXTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.4K Buy
+22,362
New +$36K ﹤0.01% 13230
2024
Q4 		– Sell
-505
Closed -$12.7K – 15370
2024
Q3 		$12.7K Buy
+505
New +$18.7K ﹤0.01% 13091
2024
Q2 		– Sell
-419
Closed -$26.3K – 15366
2024
Q1 		$26.3K Buy
+419
New +$46.7K ﹤0.01% 12814
2023
Q4 		– Sell
-92
Closed -$16.4K – 15234
2023
Q3 		$16.4K Buy
+92
New +$38.2K ﹤0.01% 12779

Other funds holding SXTP

KCM
Kathmere Capital Management Wayne, Pennsylvania $1.89B AUM 26.04% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Citadel Advisors's SXTP Position: Q2 2026 in Review

Citadel Advisors opened a new position in 60 Degrees Pharmaceuticals (SXTP) in Q2 2026: 22,362 shares worth $39.4K. The stake represents ﹤0.01% of the portfolio and ranks #13230 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in SXTP as recently as Q3 2024.

Citadel Advisors first reported a position in SXTP in Q3 2023 and has held it in 4 quarters since. 8 funds tracked by Wall St. Rank hold SXTP as of Q2 2026.

  • Citadel Advisors held 22,362 shares of 60 Degrees Pharmaceuticals worth $39.4K as of Q2 2026.
  • 60 Degrees Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
  • 60 Degrees Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13230 holding.
  • Citadel Advisors first reported a position in 60 Degrees Pharmaceuticals in Q3 2023 and has held it in 4 quarters since.
  • 8 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.